MRD Clinical Updates in Chronic Lymphocytic LeukemiaContains 1 Component(s) Includes a Live Web Event on 12/16/2020 at 1:30 PM (EST)
Learn how to use MRD testing to improve patient care. Expert faculty will discuss why MRD testing is important in managing CLL and how to best incorporate MRD testing into the treatment plan.
Optimizing Outcomes for Patients with Urothelial Carcinoma: Recent Clinical UpdatesContains 5 Component(s), Includes Credits
Component Credit Type State/Medical Type Available Credits Earned Credits CME/CNE/Certificate of Participation Medical CME 0.75 0.00 CME/CNE/Certificate of Participation Medical CNE 0.75 0.00 CME/CNE/Certificate of Participation Medical Certificate of Participation 0.75 0.00
In a recent survey of community cancer care professionals conducted by the Association of Community Cancer Centers, bladder was reported to be one of the most commonly diagnosed cancers after breast, lung, prostate, and colorectal. For many community oncologists, it is hard to stay abreast of clinical updates and changing treatment recommendations across all tumor types. This initiative will summarize recent clinical data for immunotherapies and emerging targeted therapies used to treat advanced and metastatic urothelial carcinoma. Strategies for identification and management of treatment-related adverse events, as well as effective solutions for improving multidisciplinary care coordination, will also be covered.
Patient-Reported Outcomes in Immuno-Oncology: An Educational SeriesContains 10 Component(s)
In this educational webinar series, hear from experts in the field discuss the basics of PROs, how PROs can be integrated into IO clinical care, and how PROs can be used in IO clinical trials.
Case Studies in IO Webcast: A Closer Look at Care DeliveryContains 4 Component(s)
Organized around four case studies, the discussion will focus on current clinical evidence for optimal selection of immunotherapy and use of combination therapy. Topics covered include monitoring for and managing irAEs, care coordination and communication with non-oncology specialists, and assessment of institution- or practice-specific gaps in IO integration. Shared decision-making, toxicity management, reimbursement, and survivorship will also be discussed. This activity is supported by an educational grant from Bristol Myers Squibb.
Early Integration of Pathology Into the Cancer Service LineContains 1 Component(s)
ACCC Pathology Webinar
|Access Date||Quiz Result||Score||Actions|